GLP-1 therapy is generally recommended for individuals diagnosed with type 2 diabetes who require additional glycemic control, patients with a body mass index (BMI) greater than 27, especially those with weight-related comorbidities, and those not achieving target blood glucose levels with metformin or other oral hypoglycemic agents
Hypothyroidism, even in its subclinical form, is associated with: Higher fasting insulin Increased HOMA-IR (a measure of insulin resistance) Elevated fasting glucose and hemoglobin A1C in some cases While GLP-1s can improve glycemic control, their effectiveness may be reduced in the presence of uncontrolled thyroid disease
On the other hand, Liraglutide works similarly by activating the GLP-1 receptor, but it also slows down gastric emptying and promotes satiety
Buyers should also confirm shipping, taxes, return limits, and the number of vials shown in the cart before payment
OrderlyMeds is self-pay only and does not file claims, even for branded Wegovy or Zepbound